Fundamental Analysis
By analyzing seasonally adjusted quarterly revenue, one can gauge the trend of stock. However, please note that stock prices can sometimes lead fundamental data, so it should be accompanied by other leading indicators for better judgment.
Basic Information
Basic information of individual stocks, as well as their respective sectors and industries.
Company Introduction
Business Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Company Website
Disclaimer
1. The information provided is for reference only and does not constitute any guarantee of profits or specific stock and price point recommendations.
2. The information is not complete; for comprehensive data, please refer to the relevant websites.
3. All stock market data analyses are subject to survivorship bias.
